Background. Although many children's hospitals have established antimicrobial stewardship programs (ASPs), data-driven benchmarks for optimizing antimicrobial use across centers are lacking. We developed a multicenter quality improvement collaborative focused on sharing data reports and benchmarking antimicrobial use to improve antimicrobial prescribing among hospitalized children.
To combat the growing problem of antibiotic resistance, the White House published the National Action Plan for Combating Antibiotic-Resistant Bacteria, which recommends that, by 2020, all acute care hospitals implement an antimicrobial stewardship program (ASP) and reduce inappropriate inpatient antimicrobial prescribing by 20% [1] . In response to this report, the Joint Commission will evaluate hospitals on the presence of a formal ASP, and the Centers for Medicare and Medicaid Services will require that hospitals have an active ASP as a condition for participation [2] .
Since 2009, a rapid increase in the presence of pediatric ASPs has been observed [3] . A survey conducted in 2011 found that 31 of 42 children's hospitals that submitted data to the Pediatric Health Information System (PHIS) database either had or were planning to develop an ASP [4] . It is important to note that almost all of these hospitals were performing stewardship activities. Therefore, a quality improvement collaborative was formed to share best practices and establish benchmarks among hospitals dedicated to improving the use of antimicrobial agents in children. Here, we describe formation of the Sharing Antimicrobial Reports for Pediatric Stewardship (SHARPS) collaborative and summarize the first group of initiatives undertaken by SHARPS hospitals.
METHODS
Created in the fall of 2013, the SHARPS collaborative began with a leadership team of 3 pediatric infectious diseases physicians, a study coordinator, and 2 data analysts working with 7 freestanding US children's hospitals, each with a dedicated pharmacist and physician leader. In June 2014, the collaborative began enrolling additional interested hospitals on a rolling basis. Each of these hospitals had a pharmacist and/or physician dedicated to antimicrobial stewardship.
After agreeing to join the collaborative, each site completed a survey to describe if a formal ASP was in place and to describe the characteristics of their antimicrobial stewardship efforts. A formal ASP was defined as a comprehensive program that functions continuously to monitor antimicrobial use and dedicates salary full-time equivalents (FTEs) to support a clinical pharmacist and/or pediatric infectious diseases physician [4] . Data obtained from each hospital included FTEs (if applicable) for physicians, pharmacists, infection preventionists, and data analysts dedicated to the ASP; the type(s) of stewardship strategies used (eg, prospective audit, previous authorization); antimicrobial agents monitored by the ASP; and hospital demographic data (census, number of beds, and payer mix).
Collaborative Activities
The collaborative provided comparative data reports to the sites to help identify areas in which antimicrobial use can be improved. All reports were generated from the Pediatric Health Information System (PHIS) database. The PHIS database is maintained by the Children's Hospital Association (CHA) and is an administrative database that contains inpatient, emergency department, ambulatory surgery, and observation data from 47 not-for-profit tertiary care pediatric hospitals in the United States. These hospitals are affiliated with the CHA (Mission, KS). For the purposes of external benchmarking, participating hospitals provide discharge/ encounter data including demographics, diagnoses, procedures, and resource utilization data (eg, pharmaceuticals used, imaging, and laboratory results). Data are deidentified at the time of data submission and subjected to a number of reliability and validity checks before being included in the database.
Antimicrobial-use reports were provided to the sites that submit data to the PHIS database. The first set of reports included each hospital's (1) overall antimicrobial days of therapy (DOT) per 1000 patient-days (as a general measure of antimicrobial use and the standard measure currently recommended by the Centers for Disease Control and Prevention) (Supplemental Figure 1) , (2) percentage of narrow-spectrum penicillin use in uncomplicated community-acquired pneumonia (as an example of prescribing for a common pediatric condition with an established guideline), and (3) the DOT per 1000 patient-days of carbapenem use in patients undergoing bone marrow transplant (as an example of broad-spectrum antibiotic prescribing for high-risk patients). These reports were selected to provide hospitals a global evaluation of their antimicrobial use and examples of the type of benchmarking data they could be provided. Other reports that provided length of therapy (LOT) in addition to DOT were developed. LOT focuses only on the duration of therapy and does not include the number of antimicrobial agents a patient receives. For example, a patient who received 2 antimicrobial agents for 5 days has a DOT of 10 and LOT of 5. The ratio of DOT to LOT was also calculated and provided hospitals an understanding of the number of antimicrobial agents patients were being prescribed. The ratio of observed to expected antimicrobial use was calculated for the different service lines (eg, neonatal intensive care unit). The expected duration of antibiotic use was calculated as the Winsorized mean duration of use for each antibiotic and route of administration according to All Patients Refined-Diagnosis Related Groups version 24 and severity level from 11 years of PHIS data (2002-2012) across all institutions. Observed-toexpected (O/E) service-line ratios were then calculated as the sum of observed DOT divided by the sum of expected DOT for each institution and service line (Supplemental Figure 2) . All sites were encouraged to work with SHARPS data analysts (B. R. L. and C. T.) to develop customized antimicrobial-use reports in additional areas they felt might have excess antimicrobial use.
In addition to this antimicrobial-use benchmarking, an essential role of the collaborative is to provide opportunities for sites to learn from each other. To accomplish this goal, first, a listserv was initiated and is maintained for participants to ask stewardship-related questions and to obtain advice on challenging treatment strategies. Second, SHARPS hosts a monthly webinar during which sites present current stewardship activities and obtain feedback on ways to improve antimicrobial use. Last, an annual in-person meeting takes place each June at the International Pediatric Antimicrobial Stewardship Conference, which facilitates networking and sharing of additional information on methods to perform antimicrobial stewardship. On January 20, 2016, hospitals were asked how the data reports and/or webinars have affected their stewardship efforts.
RESULTS
As of January 1, 2016, 36 hospitals comprised the SHARPS collaborative, 32 of which submitted data to the PHIS database. A description of the hospitals and their stewardship efforts are provided in Table 1 .
Thirty hospitals provided financial support to their ASP. The total median FTE provided for ASPs is 0.75 (interquartile range [IQR], 0.45-1.4). The median FTEs provided to physicians and pharmacists among the hospitals are 0.25 (IQR, 0.05-0.50) and 0.50 (IQR, 0.00-1.00), respectively. Three hospitals provided FTE support for a data analyst. In addition, 25 hospitals had an infection preventionist involved with their program, and 3 reported dedicating part of an infection preventionist's FTE toward working with the ASP.
A key aspect of the collaborative was the development of antimicrobial-use reports (Table 2) . A total of 26 reports were developed that provided comparative hospital data for overall and specific antimicrobial use based on clinical conditions (eg, pneumonia, cellulitis), patient populations (eg, oncology), and specific service lines (eg, surgery). In addition to the standard DOT per 1000 patient-days metric, reports were created with metrics determined by the participants to be helpful in understanding their data. These metrics included the percentage of narrow-spectrum antibiotic use for community-acquired pneumonia, LOT per 1000 patient-days, DOT/LOT ratio, and O/E antimicrobial-use ratio.
These data reports have resulted in 19 stewardship interventions at SHARPS hospitals ( Table 3 ). The interventions include formulary restriction/prior authorization and prospective audit with feedback, core antimicrobial stewardship strategies recommended by the Infectious Diseases Society of America; antibiotic treatment guidelines with electronic order sets for community-acquired pneumonia, necrotizing enterocolitis, fever and neutropenia, and appendicitis; use of rapid diagnostic techniques with antimicrobial stewardship to improve the use of clindamycin in skin and soft-tissue Staphylococcus aureus infection; requiring indications for linezolid and vancomycin use; monitoring the use of intravenous medications that can be administered effectively orally; and discontinuing additional antibiotics when a patient is identified to have Clostridium difficile colitis.
The webinars and annual meetings have helped SHARPS hospitals implement effective stewardship interventions and obtain critical financial resources. Since the inception of the collaborative, 27 webinars and 3 annual meetings have been conducted. Four of the webinars were focused on quality improvement techniques and aspects of reliability that the programs could use in implementing their interventions. The remaining webinars and annual meetings featured SHARPS hospital presentations that outlined interventions supported by the collaborative and the successes and barriers that they had encountered. These webinars served to introduce SHARPS hospitals to strategies for conducting the core elements of antimicrobial stewardship and mechanisms to working in high-risk settings such as neonatal intensive care units. Last, the data obtained and shared with the hospitals regarding financial support (FTEs) have helped several hospitals obtain additional resources for their stewardship efforts. 
DISCUSSION
In this report, we describe the establishment of an antimicrobial stewardship quality improvement collaborative, SHARPS, among acute care children's hospitals in the United States. The majority of hospitals (31 of 36) in the collaborative provide financial support to ASP leadership. The collaborative has provided a novel suite of benchmarking data reports and a learning environment that shares best practices to facilitate the development and implementation of successful stewardship interventions.
Nationally based quality improvement collaboratives have been successful in improving the care of children, reducing central line-associated bloodstream infections, peritoneal dialysis-associated peritonitis, and surgical-site infections by 56%, 33%, and 21%, respectively [5] [6] [7] . These collaboratives focused on measuring the implementation of standard bundles to prevent healthcare-associated infections. In the SHARPS collaborative, standard approaches/bundles were not recommended. Because each hospital has a unique social structure, antimicrobial-use culture, and areas of antimicrobial concern, benchmarking data were provided to help each hospital identify personalized targets for antimicrobial stewardship efforts. Additional research on optimal methods and implementation is needed.
A key aspect of the collaborative was the development of comparative or benchmarking antimicrobial-use reports to help hospitals identify potential areas in which to implement stewardship interventions. The strategy of providing benchmarking data has been used among a network of large academic centers that provided hospitals their O/E antimicrobial-use ratios according to service line to identify areas of improvement [8] . The Centers for Disease Control and Prevention (CDC) developed the Standardized Antimicrobial Administration Ratio (SAAR), a National Quality Foundation-endorsed measure. This metric will provide hospitals that deliver their antimicrobial-use data to the CDC a risk-adjusted O/E that can be used in the tracking and reporting of ASP data that will be required by the Joint Commission and other regulatory agencies [2, 9, 10] . Although these benchmarking metrics seem to be helpful, data that demonstrate that they will help improve antimicrobial use are needed.
Another benefit to a collaborative approach to antimicrobial stewardship is the development of innovative metrics and interventions and the potential to conduct prospective studies, including clinical trials. At this time, no metric or metrics have been developed to be the gold standard in measuring the effectiveness of an ASP. One likely gold-standard metric is the percentage of appropriate use in the hospital; a collaborative such as SHARPS has the potential to develop a sustainable method for obtaining these data. In addition, innovative interventions to improve antimicrobial use in high-risk settings can be shared among the collaborative, resulting in a greater effect of these strategies. Last, as innovative interventions are implemented, prospective studies can be conducted to aid in our understanding of the true impact of the ASP.
As ASPs are continuing to be developed, collaborative efforts are needed to help institutions implement effective programs. Recent data from the CDC reveal that a national coordinated effort among ASPs and infection prevention programs will save 39 000 lives from antimicrobial-resistant hospital-acquired infections over a 5-year period [11] . To our knowledge, the SHARPS collaborative is the first attempt at coordinating such an effort; however, more work is needed to optimize the targets, content, and format of benchmarking data reports and to develop best stewardship practices tailored to the varied settings and patient populations.
